Subject: Fwd: Retatrutide Is Too Good… AndThat’s The Problem
From: [email-masked]
To: "[email-masked]" <[email-masked]>
Date: Tue, 24 Mar 2026 22:14:11 -0400

---------- Forwarded message ----------
From: Dave Knapp from On The Pen <[email-masked]>
Date: Mar 24, 2026 at 9:24 PM -0400
To: [email-masked]
Subject: Retatrutide Is Too Good… And That’s The Problem

> There’s a lot shifting right now in the world of GLP-1s, and if you rely on compounded or research-grade options, this week’s updates may feel especially important.
> ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     
> Forwarded this email? Subscribe here for more
> Retatrutide Is Too Good… And That’s The Problem
> On The Pen GLP-1 News
> Mar 25
>
> READ IN APP
>
> There’s a lot shifting right now in the world of GLP-1s, and if you rely on compounded or research-grade options, this week’s updates may feel especially important.
> From new signals out of Washington that could impact access, to powerful new data on next-generation treatments like retatrutide, to where drug companies are heading next…things are moving quickly on multiple fronts.
> We break it all down in this week’s episode, what’s changing, what it could mean for you, and what to keep an eye on next.
> The Throttling of Compounded GLP-1sFDA vs Telehealth, What’s Really HappeningThe Truth About “Research Peptides”The Rule That Created the Black Market If You Rely on This, Here’s What’s ComingWhy They Want You Back on Branded DrugsRetatrutide Might Be the Most Powerful YetThe Data That Changes Everything (Diabetes + Weight Loss)What Comes After GLP-1s, The Next Wave
> Retatrutide Is Too Good… And That’s The Problem
> Dave Knapp GLP-1 Industry Insider
> Episode
> Leave a comment
> VISIT OUR SPONSORS!
> You’re currently a free subscriber to On The Pen. For premium access to insider articles, upgrade to paid.
> Upgrade to paid
>
> Share
>
>
> Like
> Comment
> Restack
>
> © 2026 David Knapp
> On The Pen, PO Box 541, Cedar Falls, IA 50613
> Unsubscribe